Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma - Concepedia

Concepedia

Publication | Open Access

Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma

DOI Full Paper Access

15

Citations

29

References

2022

Year

Jianlong Jia, Latai Ga, Yang Liu, Zhiyi Yang, Yue Wang, Xuanze Guo, Rui‐Chen Ma, Ruonan Liu, Tianyou Li, Zeyao Tang,

Frontiers in Immunology

Abstract

<i>SPINK1</i> could be a potential biomarker for the early detection, targeted therapy, and prediction of ICB treatment response in the management of HCC.

References

	Year	Citations

Page 1